التفاصيل البيبلوغرافية
| العنوان: |
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents : a cohort study from the GESMD |
| المؤلفون: |
Vilorio-Marqués, Laura, Castañón Fernández, Christelle, Mora, Elvira, Gutiérrez, Lorena, Rey Bua, Beatriz, Jiménez Lorenzo, Maria José, DÃaz-Beyá, Marina, Vara Pampliega, Miriam, Molero, Antonieta, Sánchez-GarcÃa, JoaquÃn, Calabuig, Marisa, Cedena, MarÃa Teresa, Chen-Liang, Tzu, DÃaz Santa, Johana Alejandra, Padilla, Irene, Hernández, Francisca, DÃez, Rosana, Asensi, Pedro, Xicoy, Blanca, Sanz, Guillermo, Valcárcel, David, Diez-Campelo, MarÃa, Bernal, Teresa, Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona |
| سنة النشر: |
2022 |
| المجموعة: |
Universitat Autònoma de Barcelona: Dipòsit Digital de Documents de la UAB |
| الوصف: |
The authors declared the following potential conflict of interest with respect to the research, authorship, and/or publication of this article: T.B. has received support for attending meetings and/or travel from Jazz Pharmaceutical, honoraria from Jazz Pharmaceutical, BMS, and Pfizer. D.V. has received honoraria from Celgene/BMS, Amgen, Novartis, Jazz Pharmaceuticals, and Pfizer and support for attending meetings and/or travel from Amgen, BMS/Celgene, and Jazz. M.D.-C. reports honoraria and membership on entity's Board of directors or advisory committees from Novartis, BMS, and Takeda. Dr G.S. has received personal fees from AbbVie, Amgen, and Astellas and has received research funding from Celgene/BMS Janssen-Cilag, Novartis, Roche, and Takeda. ; Background: The consequences of infectious toxicity of hypomethylating agents (HMAs) on overall survival (OS) of patients diagnosed with high-risk myeloid neoplasms have not been thoroughly investigated. Objectives: We aimed to evaluate whether infectious events (IEs) negatively influenced the results of HMA treatment in a real-world setting. Design: Observational study. Methods: We obtained data from 412 non-selected consecutive patients from 23 Spanish hospitals who were diagnosed with high-risk myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia and were treated with HMA. HMAs received after chemotherapy or stem cell transplant were excluded. All IEs were recorded. Outcomes included OS, modifications to the pre-planned treatment, incidence and characteristics of IEs, hospitalization, red blood cell transfusions, and factors associated with infection. Results: The rate of infection was 1.2 per patient/year. Next-cycle delay (p = 0.001) and hospitalizations (p = 0.001) were significantly influenced by IEs. Transfusion requirements during each cycle were significantly higher after infection compared with cycles without infection (coefficient = 1.55 [95% confidence interval (CI) = 1.26-1.84], p < 0.001). The median number of cycles ... |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| تدمد: |
20406207 |
| العلاقة: |
Therapeutic Advances in Hematology; Vol. 13 (2022); https://ddd.uab.cat/record/270615Test; urn:10.1177/20406207221127547; urn:oai:ddd.uab.cat:270615; urn:scopus_id:85139196008; urn:pmid:36199837; urn:pmc-uid:9527993; urn:pmcid:PMC9527993; urn:oai:pubmedcentral.nih.gov:9527993; urn:oai:egreta.uab.cat:publications/c9c818a1-2c0b-4efa-8801-4f13832b23a4 |
| الإتاحة: |
https://ddd.uab.cat/record/270615Test |
| حقوق: |
open access ; Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. ; https://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: |
edsbas.1F68BC95 |
| قاعدة البيانات: |
BASE |
Full Text Finder